Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.

Original languageEnglish (US)
Pages (from-to)4111-4120
Number of pages10
JournalJournal of Clinical Investigation
Volume123
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Clinical Trials
Pharmacology
Constipation
Esophageal Diseases
Visceral Pain
Colonic Diseases
Gastroparesis
Translational Medical Research
Gastrointestinal Diseases
Opioid Analgesics
Diarrhea
Biomarkers
Quality of Life
Motor Disorders
Gastroenterologists

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. / Camilleri, Michael.

In: Journal of Clinical Investigation, Vol. 123, No. 10, 01.10.2013, p. 4111-4120.

Research output: Contribution to journalArticle

@article{64270d947eb9443cb183b9fb5195f0a3,
title = "Pharmacological agents currently in clinical trials for disorders in neurogastroenterology",
abstract = "Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.",
author = "Michael Camilleri",
year = "2013",
month = "10",
day = "1",
doi = "10.1172/JCI70837",
language = "English (US)",
volume = "123",
pages = "4111--4120",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - Pharmacological agents currently in clinical trials for disorders in neurogastroenterology

AU - Camilleri, Michael

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.

AB - Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.

UR - http://www.scopus.com/inward/record.url?scp=84885080634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885080634&partnerID=8YFLogxK

U2 - 10.1172/JCI70837

DO - 10.1172/JCI70837

M3 - Article

VL - 123

SP - 4111

EP - 4120

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -